



(NSCLC = non-small cell lung cancer, PS = performance-status, R = randomization, EGFR = epidermal growth factor receptor, IHC = immunohistochemistry; PD = progressive disease)

According to their status at this time, patients then received 2nd line pemetrexed until their second disease progression, followed by palliative care until death. Patients not given second-line therapy directly received best supportive care until death.